RSAD2

Across TCGA pan-cancer cohorts, RSAD2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RSAD2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RSAD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RSAD2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, LUAD, and HNSC are the cancer types where RSAD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	1.000	0.407	.004	6	view →
LUAD	DFS	Tertile	III,IV	0.384	1.000	.024	5	view →
HNSC	OS	Tertile	All	0.839	0.622	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RSAD2–LSCC (DFS)

Open the LSCC breakdown →